Trials / Completed
CompletedNCT01711970
A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Müllerian Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open label, dose escalating, Phase I/II study, measuring mainly the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel in patients with platinum resistant ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2017-05-03
- Completion
- 2017-05-03
- First posted
- 2012-10-23
- Last updated
- 2020-04-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01711970. Inclusion in this directory is not an endorsement.